-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
SAB Biotherapeutics, Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2020 to 31 Dec 2025.
- SAB Biotherapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $173,985, a 56% increase year-over-year.
- SAB Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $168,299,452.
- SAB Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $1,172,626, a 102% decline from 2023.
- SAB Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $66,773,137, a 6251% increase from 2022.